Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epetraborole in Treatment-refractory MAC Lung Disease
NCT05327803Phase 3Terminated
- Sponsor
- AN2 Therapeutics, Inc.
- Start
- May 2022
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 3 trial of epetraborole in mycobacterium avium complex pulmonary disease (MAC-PD), sponsored by AN2 Therapeutics, Inc.. Started May 2022; status: terminated.
02
Drugs
epetraborole
03
Conditions
mycobacterium avium complex pulmonary disease (MAC-PD)
Beyond the preview
Go deeper on NCT05327803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05327803.